Simponi Aria (Golimumab) for Spondylitis

Overview
- Approval: Simponi Aria is approved by the U.S. Food and Drug Administration (FDA) to treat adults with active ankylosing spondylitis.
- Type: It is an immunomodulator, specifically a biologic disease-modifying antirheumatic drug (DMARD).
- Mechanism: Simponi Aria is a Show Full Answer

Simponi Aria (Golimumab) for Spondylitis

Overview:
- Approval: Simponi Aria is approved by the U.S. Food and Drug Administration (FDA) to treat adults with active ankylosing spondylitis.
- Type: It is an immunomodulator, specifically a biologic disease-modifying antirheumatic drug (DMARD).
- Mechanism: Simponi Aria is a genetically engineered antibody that works by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.

Administration:
- Method: Administered as an intravenous infusion.
- Frequency: Every eight weeks after initial loading doses.
- Form: Comes in a single-dose vial.

Side Effects:
- Common:
- Upper respiratory tract infection
- Increased liver enzymes
- Viral infection
- Lowered blood count
- High blood pressure
- Rash
- Rare but Serious:
- Severe infections
- Congestive heart failure
- Increased risk for lymphoma
- Demyelinating disorders such as multiple sclerosis
- Lupus-like syndrome
- Hypersensitivity reactions

For more details about this treatment, you can visit the official [Simponi Aria website](https://www.simponiaria.com).

 This AI-generated response comes from MySpondylitisTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Simponi Aria (Golimumab) for Spondylitis | MySpondylitisTeam

Simponi (Golimumab) for Spondylitis | MySpondylitisTeam